Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;130(6):827-838.
doi: 10.1007/s00702-023-02635-4. Epub 2023 May 11.

The heterogeneity of Parkinson's disease

Ullrich Wüllner  1 , Per Borghammer  2 , Chi-Un Choe  3 , Ilona Csoti  4 , Björn Falkenburger  5 , Thomas Gasser  6 , Paul Lingor  7   8 , Peter Riederer  9   10
Affiliations
Review

The heterogeneity of Parkinson's disease

Ullrich Wüllner et al. J Neural Transm (Vienna). 2023 Jun.

Abstract

The heterogeneity of Parkinson's disease (PD), i.e. the various clinical phenotypes, pathological findings, genetic predispositions and probably also the various implicated pathophysiological pathways pose a major challenge for future research projects and therapeutic trail design. We outline several pathophysiological concepts, pathways and mechanisms, including the presumed roles of α-synuclein misfolding and aggregation, Lewy bodies, oxidative stress, iron and melanin, deficient autophagy processes, insulin and incretin signaling, T-cell autoimmunity, the gut-brain axis and the evidence that microbial (viral) agents may induce molecular hallmarks of neurodegeneration. The hypothesis is discussed, whether PD might indeed be triggered by exogenous (infectious) agents in susceptible individuals upon entry via the olfactory bulb (brain first) or the gut (body-first), which would support the idea that disease mechanisms may change over time. The unresolved heterogeneity of PD may have contributed to the failure of past clinical trials, which attempted to slow the course of PD. We thus conclude that PD patients need personalized therapeutic approaches tailored to specific phenomenological and etiologic subtypes of disease.

Keywords: Disease mechanism; Inflammation; Parkinson’s disease; Pathophysiology; Personalized medicine; Phenotypes.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ahmed H, Abushouk AI, Gabr M, Negida A, Abdel-Daim MM. Parkinson’s disease and pesticides: a meta-analysis of disease connection and genetic alterations. Biomed Pharmacother. 2017;90:638–649. doi: 10.1016/j.biopha.2017.03.100. - DOI - PubMed
    1. Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, Hibbert S, Budnik N, Zampedri L, Dickson J, Li Y, Aviles-Olmos I, Warner TT, Limousin P, Lees AJ, Greig NH, Tebbs S, Foltynie T. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10103):1664–1675. doi: 10.1016/S01406736(17)31585-4. - DOI - PMC - PubMed
    1. Attems J, Toledo JB, Walker L, Gelpi E, Gentleman S, Halliday G, Hortobagyi T, Jellinger K, Kovacs GG, Lee EB, Love S, McAleese KE, Nelson PT, Neumann M, Parkkinen L, Polvikoski T, Sikorska B, Smith C, Grinberg LT, Thal DR, Trojanowski JQ, McKeith IG. Neuropathological consensus criteria for the evaluation of Lewy pathology in post-mortem brains: a multi-centre study. Acta Neuropathol. 2021;141:159–172. doi: 10.1007/s00401-020-02255-2. - DOI - PMC - PubMed
    1. Bartl M, Dakna M, Schade S, et al. Longitudinal change and progression indicators using the movement disorder society-unified Parkinson's disease rating scale in two independent cohorts with early Parkinson's disease. J Parkinsons Dis. 2022;12(1):437–452. doi: 10.3233/JPD-212860. - DOI - PubMed
    1. Beach TG, Adler CH, Sue LI, Shill HA, Driver-Dunckley E, Mehta SH, Intorcia AJ, Glass MJ, Walker JE, Arce R, Nelson CM, Serrano GE. Vagus nerve and stomach synucleinopathy in Parkinson's disease, incidental lewy body disease, and normal elderly subjects: evidence against the "body-first" hypothesis. J Parkinsons Dis. 2021;11(4):1833–1843. doi: 10.3233/JPD-212733. - DOI - PMC - PubMed

Publication types

Substances